News - 2013

Halloran Principal Consultant, Emily Walsh, Ph.D., has joined Entrepreneurship Lab NYC as a mentor to its network of aspiring entrepreneurs in New York City. Bio and Health Tech Entrepreneurship Lab NYC is a prestigious 6-month training and mentorship program for aspiring entrepreneurs in New York City's life sciences and healthcare technology community. The Lab provides extensive support to graduate students of science, post-docs, early-career researchers and engineers interested in forming new biotech and health tech ventures.

For more information about the program, please click here.

Halloran Chief Operating Officer, Greg Dombal, has been featured in an article published online by Nature Medicine about FDA's use of the 'breakthrough' designation, which was just awarded for the first time last month. Greg's expertise in regulatory guidelines and submissions lent itself well to the discussion.

First 'breakthrough' drugs designated, but dilution worries linger by Elie Dolgin

As published in Nature Medicine 19, 116–117 (2013).

Please click here to read the article in its entirety online.

Laurie Halloran will be among the distinguished faculty presenting at Tufts Center for the Study of Drug Development 40th Annual Postgraduate Course in Clinical Pharmacology, Drug Development and Regulation.

The only course that links clinical pharmacology and trial design and the regulatory review of new drugs and biologics - taught by leading experts from industry, the FDA and academia. 

For more information and to register, please click here.